Ceftobiprole for Treatment of Complicated <i>Staphylococcus aureus</i> Bacteremia

Abstract

Ceftobiprole was noninferior to daptomycin with respect to overall treatment success in patients with complicated <i>S. aureus</i> bacteremia. (Funded by Basilea Pharmaceutica International and the U.S. Department of Health and Human Services; ERADICATE ClinicalTrials.gov number, NCT03138733.).